Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles.
Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles.
复制标题
A 型肉毒毒素治疗弗雷综合征的功效和安全性：来自 22 篇已发表文章的证据
DOI：
10.1002/cam4.504
复制
发表时间：
2015-11
期刊：
影响因子：
4
通讯作者：
Cai ZG
中科院分区：
文献类型：
--
作者：
Xie S;Wang K;Xu T;Guo XS;Shan XF;Cai ZG
弗雷氏综合征（FS）是腮腺手术后不可避免的后遗症。虽然有几种治疗方法，但它们的疗效是短期的或伴有不可接受的并发症。在过去的二十年里，A型肉毒毒素（BTXA）被广泛用于治疗FS。虽然最近报道了几项系统评价，但它们相互矛盾，存在明显的缺陷。因此，我们进行了客观的系统评价，以确定肉毒毒素是否是FS的有效和安全的治疗方法。2015年1月16日对PubMed、Web of Science、Ovid、Embase和Cochrane图书馆进行文献检索。采用比例荟萃分析和相应的95%置信区间（CI）评价BXTA治疗FS的疗效和安全性。经过两位独立作者的审查，共检索了499条记录，包括22篇文章和23项研究。通过对有效率、并发症发生率的统计分析，评价肉毒毒素的有效性和安全性。结果显示，BTXA治疗FS的有效率为98.5% (95% CI = 0.971 ~ 0.994)，并发症发生率为3.6% （95% CI = 0.017 ~ 0.061）。总之，我们的研究支持肉毒毒素对FS患者的治疗有意义的益处。然而，由于缺乏强有力的证据，未来的研究需要设计良好的纳入标准和多中心随机对照试验，以提供更可信的证据，如果可能的话。
Frey’s syndrome (FS) is an unavoidable sequela following the surgery of the parotid gland. Although several treatment methods are available, their efficacy is short term or accompanied by unacceptable complications. In the past two decades, botulinum toxin type A (BTXA) has been widely used to treat FS. Although several systematic reviews have been reported recently, they were conflicting and with obvious deficiencies. Thus, we performed an objectively systematic review to determine whether BTXA is an effective and safe treatment for FS. A literature retrieval covering PubMed, Web of Science, Ovid, Embase and Cochrane library was performed on 16 January, 2015. Proportion meta-analysis and corresponding 95% confidence interval (CI) were performed to evaluate the efficacy and safety of BXTA in treatment of FS. A total of 499 records were retrieved and 22 articles with 23 studies were included after scrutiny by two independent authors. Statistical analyses regarding the effective rate, incidence of complications were used to estimate the efficacy and safety of BTXA. Our results suggested that the effective rate of BTXA for treatment of FS is 98.5% (95% CI = 0.971–0.994) and the incidence of complication is 3.6% (95% CI = 0.017–0.061). In conclusion, our study supports that BTXA produces meaningful benefits on the treatment of patients with FS. However, owing to lack of strong evidence, future studies with well-designed inclusion criteria and multicenter randomized controlled trials are needed to give more credible evidence, if possible.